ArticleInternational journal of radiation oncology, biology, physics2016
Focal Radiation Therapy Dose Escalation Improves Overall Survival in Locally Advanced Pancreatic Cancer Patients Receiving Induction Chemotherapy and Consolidative Chemoradiation.
Article in International journal of radiation oncology, biology, physics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 219 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I Study of Concurrent Nab-Paclitaxel + Gemcitabine With Hypofractionated, Ablative Proton Therapy for Locally Advanced Pancreatic Cancer
Pilot Study of Intravenous Contrast-Enhanced Cone Beam Computed Tomography (CT) in Patients Receiving Radiotherapy
Who cites it
219 citing papers in PubMed.
- A Randomized Controlled Trial of Stereotactic Body Radiation Therapy Versus Chemoradiation Following Induction Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer.Journal of gastrointestinal cancer · 2025Trial
- Trial
- Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial.The Lancet. Oncology · 2023Trial
- Trial
- MRI guided stereotactic radiotherapy for locally advanced pancreatic cancer.The British journal of radiology · 2018Trial
- Global Perspectives on Radiotherapy Utilization for Pancreatic Ductal Adenocarcinoma.Journal of gastrointestinal cancer · 2026Article
- Article
- Practical Considerations in the Radiotherapy Treatment Planning for SBRT Pancreas Program.Current oncology (Toronto, Ont.) · 2026Review
- Assessment of dose distribution in pancreatic SABR in the presence of a metallic biliary stent using Monte Carlo modeling.Journal of applied clinical medical physics · 2026Article
- Dynamic tumor tracking for locally advanced pancreatic cancer: precision in motion.Translational cancer research · 2026Article
- Article
- Optical Flow-Guided Analysis of Intrafractional Anatomical Variations in Pancreatic Tumors and Organs at Risk During Magnetic Resonance-Guided Adaptive Radiation Therapy Under Abdominal Compression.Advances in radiation oncology · 2026Article
- Research progresses on FLASH radiotherapy and its application for the treatment of digestive system tumors.Discover oncology · 2026Review
- Stereotactic Adaptive Radiation Therapy for Borderline Resectable or Locally Advanced Pancreatic Cancer to Minimize Gastrointestinal Toxicity (ARTIA-Pancreas): Protocol for a Single-Arm Prospective Trial.JMIR research protocols · 2026Article
- Biologically effective doses for α/β = 10 (BEDFrontiers in oncology · 2026Article
- Gene Mutations and Related Molecular Events in Distant Metastasis of Cervical Cancer: A Review.International journal of medical sciences · 2026Review
- Proton therapy for pancreatic cancer: real-world single-center experience of efficacy, toxicity, and predictors of outcome.Frontiers in oncology · 2026Article
- Hydrogel adhesives for upper gastrointestinal wound healing.Theranostics · 2026Review
- Application of intrahepatic fiducial markers in carbon ion radiotherapy for pancreatic cancer-Achieving higher precision treatment.Journal of applied clinical medical physics · 2026Article
- Radiotherapy in the management of PDAC, from past to present.Translational oncology · 2026Review
159 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
purposeTo review outcomes of locally advanced pancreatic cancer (LAPC) patients treated with dose-escalated intensity modulated radiation therapy (IMRT) with curative intent. METHODS AND MATERIALS: A total of 200 patients with LAPC were treated with induction chemotherapy followed by chemoradiation between 2006 and 2014. Of these, 47 (24%) having tumors >1 cm from the luminal organs were selected for dose-escalated IMRT (biologically effective dose [BED] >70 Gy) using a simultaneous integrated boost technique, inspiration breath hold, and computed tomographic image guidance. Fractionation was optimized for coverage of gross tumor and luminal organ sparing. A 2- to 5-mm margin around the gross tumor volume was treated using a simultaneous integrated boost with a microscopic dose. Overall survival (OS), recurrence-free survival (RFS), local-regional and distant RFS, and time to local-regional and distant recurrence, calculated from start of chemoradiation, were the outcomes of interest.
resultsMedian radiation dose was 50.4 Gy (BED = 59.47 Gy) with a concurrent capecitabine-based (86%) regimen. Patients who received BED >70 Gy had a superior OS (17.8 vs 15.0 months, P=.03), which was preserved throughout the follow-up period, with estimated OS rates at 2 years of 36% versus 19% and at 3 years of 31% versus 9% along with improved local-regional RFS (10.2 vs 6.2 months, P=.05) as compared with those receiving BED ≤70 Gy. Degree of gross tumor volume coverage did not seem to affect outcomes. No additional toxicity was observed in the high-dose group. Higher dose (BED) was the only predictor of improved OS on multivariate analysis.
conclusionRadiation dose escalation during consolidative chemoradiation therapy after induction chemotherapy for LAPC patients improves OS and local-regional RFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.